Comment on: “The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022”-Reference-Cited by-同舟云学术

Comment on: “The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022”

Published:2023-11-16 Issue:1 Volume:22 Page:123-124
ISSN:1175-5652
Container-title:Applied Health Economics and Health Policy
language:en
Short-container-title:Appl Health Econ Health Policy

Author:

de Vries Sieta T.^ORCID,Al-Mugoter Noral Huda S.,Petkoska Irena,Verweij Stefan^ORCID,Elferink André J. A.,Mol Peter G. M.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Health Policy,Economics and Econometrics,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40258-023-00850-4.pdf

Reference4 articles.

1. Meregaglia M, Malandrini F, Angelini S, Ciani O. The assessment of patient-reported outcomes for the authorisation of medicines in Europe: a review of European Public Assessment Reports from 2017 to 2022. Appl Health Econ Health Policy. 2023. https://doi.org/10.1007/s40258-023-00827-3.

2. European Medicines Agency (EMA). European Public Assessment Reports. https://www.ema.europa.eu/en/medicines/download-medicine-data. Accessed 13 July 2023.

3. Au HJ, Ringash J, Brundage M, Palmer M, Richardson H, Meyer RM, NCIC CTG Quality of Life Committee. Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. Expert Rev Pharmacoecon Outcomes Res. 2010;10(2):119–28. https://doi.org/10.1586/erp.10.15.

4. Haag S, Junge L, Lotz F, McGauran N, Paulides M, Potthast R, Kaiser T. Results on patient-reported outcomes are underreported in summaries of product characteristics for new drugs. J Patient Rep Outcomes. 2021;5(1):127. https://doi.org/10.1186/s41687-021-00402-1.